Literature DB >> 22522066

The mode of death in implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillator patients: results from routine clinical practice.

Joep Thijssen1, Johannes B van Rees, Jeroen Venlet, C Jan Willem Borleffs, Ulas Höke, Hein Putter, Enno T van der Velde, Lieselot van Erven, Martin J Schalij.   

Abstract

BACKGROUND: Although data on the mode of death of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy with defibrillator (CRT-D) patients have been examined in randomized clinical trials, in routine clinical practice data are scarce. To provide reasonable expectations and prognosis for patients and physicians, this study assessed the mode of death in routine clinical practice.
OBJECTIVE: To assess the mode of death in ICD/CRT-D recipients in routine clinical practice.
METHODS: All patients who underwent an ICD or CRT-D implantation at the Leiden University Medical Center, the Netherlands, between 1996 and 2010 were included. Patients were divided into primary prevention ICD, secondary prevention ICD, and CRT-D patients. For patients who died during follow-up, the mode of death was retrieved from hospital and general practitioner records and categorized according to a predetermined classification: heart failure death, other cardiac death, sudden death, noncardiac death, and unknown death.
RESULTS: A total of 2859 patients were included in the analysis. During a median follow-up of 3.4 years (interquartile range 1.7-5.7 years), 107 (14%) primary prevention ICD, 253 (28%) secondary prevention ICD, and 302 (25%) CRT-D recipients died. The 8-year cumulative incidence of all-cause mortality was 39.9% (95% confidence interval 37.0%-42.9%). Heart failure death and noncardiac death were the most common modes of death for all groups. Sudden death accounted for approximately 7%-8% of all deaths.
CONCLUSION: For all patients, heart failure and noncardiac death are the most common modes of death. The proportion of patients who died suddenly was low and comparable for primary and secondary ICD and CRT-D patients.
Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22522066     DOI: 10.1016/j.hrthm.2012.04.021

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  9 in total

1.  Japan Implantable Devices in Coronary Artery Disease (JID-CAD) study design.

Authors:  Akihiko Shimizu; Takeshi Mitsuhashi; Takashi Nitta; Hideo Mitamura; Takashi Kurita; Haruhiko Abe; Yuji Nakazato; Naokata Sumitomo; Kazushige Kadota; Kazuo Kimura; Ken Okumura
Journal:  J Arrhythm       Date:  2014-09-12

Review 2.  Mechanisms of sudden cardiac death.

Authors:  Carsten W Israel
Journal:  Indian Heart J       Date:  2014-02-11

Review 3.  Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?

Authors:  Khang-Li Looi; Nigel Lever; Anthony Tang; Sharad Agarwal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 4.  Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.

Authors:  Neal A Chatterjee; Attila Roka; Steven A Lubitz; Michael R Gold; Claude Daubert; Cecilia Linde; Jan Steffel; Jagmeet P Singh; Theofanie Mela
Journal:  Eur Heart J       Date:  2015-08-10       Impact factor: 29.983

5.  Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer.

Authors:  Maurizio Landolina; Antonio Curnis; Giovanni Morani; Antonello Vado; Ernesto Ammendola; Antonio D'onofrio; Giuseppe Stabile; Martino Crosato; Barbara Petracci; Carlo Ceriotti; Luca Bontempi; Martina Morosato; Gian Paolo Ballari; Maurizio Gasparini
Journal:  Europace       Date:  2015-05-14       Impact factor: 5.214

6.  Efficacy of implantable cardioconverter defibrillator or cardiac resynchronization therapy compared with combined therapy in survival of patients with heart failure: a meta-analysis.

Authors:  Jin-Long Deng; Yin-Xiong Wu; Jie Liu
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

7.  Predictive value of Tpeak-Tend interval for ventricular arrhythmia and mortality in heart failure patients with an implantable cardioverter-defibrillator: A cohort study.

Authors:  Cong Xue; Wei Hua; Chi Cai; Li-Gang Ding; Hong-Xia Niu; Xiao-Han Fan; Zhi-Min Liu; Min Gu; Yun-Zi Zhao; Shu Zhang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

Review 8.  Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis.

Authors:  Sérgio Barra; Rui Providência; Anthony Tang; Patrick Heck; Munmohan Virdee; Sharad Agarwal
Journal:  J Am Heart Assoc       Date:  2015-11-06       Impact factor: 5.501

9.  Long-term follow-up of implantable cardioverter defibrillator patients with regard to appropriate therapy, complications, and mortality.

Authors:  Gustav Mattsson; Peter Magnusson
Journal:  Pacing Clin Electrophysiol       Date:  2020-01-22       Impact factor: 1.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.